This article is part of our October 2020 special issue. Download the full issue here: https://issuu.com/impacthealthmedia/docs/nmjmag18_oncology_final
On this episode, integrative clinician and researcher Isaac Eliaz, MD, LAc, shares some of the more progressive methods he uses with people who have cancer. In addition to providing an update on galectin-3 and modified citrus pectin research, Eliaz also discusses his research involving prostate cancer relapse and how he uses mushroom extracts to address breast cancer regardless of receptive status. Finally, he briefly describes his pioneering applications using therapeutic apheresis.
Isaac Eliaz, MD, LAc, is an integrative medical doctor, licensed acupuncturist, researcher, author, product formulator, and frequent guest lecturer. He has been a pioneer in holistic medicine since the early 1980s, with numerous peer-reviewed publications demonstrating the benefits of his innovative formulas and protocols.
Eliaz is the founder and medical director of Amitabha Medical Clinic in Santa Rosa, California, an integrative health center specializing in cancer and chronic conditions. Eliaz is regarded as a leading expert in galectin-3 and modified citrus pectin research, as well as a pioneer in the use of therapeutic apheresis blood filtration in the United States.
MD-Formulated. 3rd Party Researched. The Clinical Synergy Difference.
Clinical Synergy Professional Formulas is a recognized leader in advanced nutraceutical formulas, featuring first-in-class, independently researched solutions for optimal health and aging. Developed by renowned clinician and researcher, Isaac Eliaz, MD, LAc, Clinical Synergy products and protocols are recommended worldwide as effective, evidence-based solutions for today's most critical areas of health. Clinical Synergy specializes in targeted, extensively researched formulas for cellular function and healthy aging, cardiovascular and kidney function, immune balancing, detoxification, neurological health, vector-borne health concerns, microbiome support, and more.